RxDoctor Payments Data

Ruth Sarmiento, MD

Hematology & Oncology · Stockbridge, GANPI 1609893072

Payments from drug & device makers

$5,415in general payments, 2019–2025

Across 206 payments — averaging $26.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$416
  • AstraZeneca$361
  • Pfizer$324
  • Johnson & Johnson$288
  • E.r. Squibb & Sons, L.L.C.$276
  • Karyopharm Therapeutics Inc.$250
  • plus $3K from 50 others

What the payments were for

  • Food & beverage$5,27497%
  • Education$1413%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,415 in reported general payments places this provider in the 40th percentile of 370 hematology & oncology providers in Georgia.

See all hematology & oncology providers in Georgia

Medicare billing

Part B allowed, 2024
$26,241
Medicare patients
192
Services billed
406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide71$1,364,199
ImbruvicaIbrutinib61$1,013,393
SprycelDasatinib11$172,279
PromactaEltrombopag Olamine14$169,729
Everolimus12$103,649
EliquisApixaban65$47,427
Exemestane24$1,479
Letrozole75$1,178
Anastrozole26$374
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen28$371
Dexamethasone23$356
Hydroxyurea12$353
Megestrol Acetate12$339
Bicalutamide11$310
Ondansetron Hcl18$297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$77$1,364,19971 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$28$1,013,39361 claims
E.r. Squibb & Sons, L.L.C.Sprycel$276$172,27911 claims
NovartisPromacta$416$169,72914 claims
PfizerEliquis$324$47,42765 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 370 hematology & oncology providers in Georgia.

Other hematology & oncology in Stockbridge

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →